News and Comments

INTERCEPT LIVER DRUG IS GAME CHANGER FOR THE BIOTECH INDUSTRY

  Friday, January 10, 2014

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. Many people live with fatty livers, but in some of them only, the fat causes chronic inflammation of the liver - fibrosis – cirrhosis – liver failure and death. The disease is called Nonalcoholic steatohepatitis because its complications are similar to the liver disease that is caused by long-term, heavy alcohol drinking, but without being alcohol abusers. Currently there are no approved drugs to treat NASH.  More...

ARCA BIOPHARMA: A GENETICALLY TARGETED DRUG FOR ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS

  Thursday, January 09, 2014

A Colorado-based biopharmaceutical company, ARCA Biopharma (ABIO) has a genetically-targeted drug, GencaroTM (bucindolol hydrochloride), for Atrial fibrillation (AF) in patients with heart failure (HF). The drug offers a personalized medicine approach for the treatment of AF in HF, treating only individuals with certain genetic characteristics. This approach enables the selection of individuals who would most probably respond to the drug through excluding the expected non-responders, thus reducing statistically failed trial outcome, in addition to decreasing clinical trial and healthcare costs.    More...

AMGEN INVESTIGATIONAL DRUG ROMOSOZUMAB IS PROMISING FOR POSTMENOPAUSAL OSTEOPOROSIS

  Thursday, January 02, 2014

Osteoporosis is caused by a progressive decrease in bone mass and density which increases the risk of fracture. The reduced, bone mineral density (BMD) impacts the bone architecture and alters the amount and variety of proteins in the bones.  More...


Recent News_and_Comments


Archive


Tags